

Kyowa Hakko Kirin Co., Ltd.

Appendix to the Consolidated Financial Statements

Third Quarter Results for Fiscal 2008 (April 1, 2008 to December 31, 2008)

	Contents	Page
Consolidated	I. Financial results	
	1. Income	1
	2. Results by segment	1
	3. Other income	2
	4. Extraordinary income/losses	2
	5. R&D expenses	2
	6. Capital expenditure	3
	7. Depreciation expenses	3
	8. Key indicators	3
	II. Subsidiaries and affiliates	4
	III. Financial results	
Non-Consolidated	1. Net sales by division	5
R&D Pipeline		7

This document was made as a supplement to the Kessan Tanshin (financial report) for the Third Quarter of the fiscal year ending March 31, 2009. This document contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts presented here.

1. Consolidated results

1. Trends in income

Millions of yen, rounded down

	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009				
	Interim results	Apr. - Dec. results (A)	Full year results	Interim results	Apr. - Dec. results (B)	Change from previous comparable period		Full year forecast
						Change (B-A)	Change %	
Net sales	192,639	297,681	392,119	247,769	362,278	64,596	122%	457,000
Gross Profit	72,116	111,191	144,917	109,345	159,870	48,679	144%	
Selling, general and administrative expenses	53,869	78,785	105,527	80,180	117,174	38,388	149%	
Operating income (before goodwill)				33,962	49,893			56,096
Operating income	18,246	32,405	39,390	29,164	42,696	10,290	132%	46,500
Other income	2,521	3,510	4,863	3,093	3,736	226		
Other expenses	2,687	3,165	6,257	1,899	3,166	1		
Recurring income	18,080	32,750	37,996	30,357	43,265	10,515	132%	47,000
Extraordinary income	328	7,562	7,988	--	--	(7,562)		
Extraordinary expenses	406	808	7,169	4,769	13,981	13,173		
Net income before income taxes	18,002	39,504	38,815	25,588	29,284	(10,220)	74%	35,000
Corporate, local and enterprise taxes	7,125	12,105	15,228	10,150	13,555	1,450		
Corporate tax adjustment	(259)	3,149	(35)	6,798	4,799	1,649		
Income (loss) in minority interests	89	165	144	353	445	280		
Net income	11,047	24,084	23,477	8,285	10,483	(13,600)	44%	13,000

Net income per share before goodwill amortization (yen/share)

	31.32	60.55	59.03	22.79	30.80			39.36
--	-------	-------	-------	-------	-------	--	--	-------

*Before goodwill amortization are the amounts before the amortization of goodwill for the period from April 1, 2008 to December 31, 2008 (7,197 million yen) arising from the reverse acquisition (share exchange with Kirin Pharma)

2. Breakdown of results

(1) Results by operating segment

Millions of yen, rounded down

	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009				
	Interim results	Apr. - Dec. results (A)	Full year results	Interim results	Apr. - Dec. results (B)	Change from previous comparable period		Full year forecast
						Change (B-A)	Change %	
Net sales	192,639	297,681	392,119	247,769	362,278	64,596	122%	457,000
Pharmaceuticals	68,900	106,074	138,377	108,719	161,337	55,262	152%	209,000
Bio-Chemicals	43,808	66,125	86,820	45,711	67,545	1,420	102%	89,000
Chemicals	51,045	80,105	108,007	57,204	77,322	(2,783)	97%	90,000
Food	20,947	33,257	43,324	20,804	32,834	(423)	99%	43,000
Other	24,647	37,652	48,998	36,572	54,502	16,850	145%	71,000
Total	209,349	323,216	425,527	269,011	393,542	70,326	122%	502,000
Eliminations	(16,709)	(25,534)	(33,407)	(21,241)	(31,264)	(5,730)	--	(45,000)
Operating income	18,246	32,405	39,390	29,164	42,696	10,290	132%	46,500
Before goodwill amortization				33,962	49,893			56,096
Pharmaceuticals	9,733	17,351	19,961	19,699	29,662	12,311	171%	32,500
				24,013	36,134			41,128
Bio-Chemicals	4,045	6,646	9,688	5,216	7,425	778	112%	8,200
				5,529	7,894			8,826
Chemicals	3,275	6,086	7,169	2,960	3,532	(2,554)	58%	3,400
				2,984	3,569			3,449
Food	674	1,354	1,576	565	999	(355)	74%	1,100
				711	1,218			1,393
Other	456	761	838	687	1,060	298	139%	1,300
				687	1,060			1,300
Total	18,185	32,200	39,234	29,128	42,680	10,479	133%	46,500
				33,926	49,877			56,096
Eliminations	61	204	155	35	15	(188)	8%	--

*Figures representing goodwill before amortization have been italicized

(2) Overseas sales

Millions of yen, rounded down

	April 1, 2007 to March 31, 2008						April 1, 2008 to March 31, 2009			
	Interim results	Percentage of consolidated sales	Apr. - Dec. results	Percentage of consolidated sales	Full year results	Percentage of consolidated sales	Interim results	Percentage of consolidated sales	Apr. - Dec. results	Percentage of consolidated sales
Overseas sales	39,604	20.6%	59,270	19.9%	75,217	19.2%	59,032	23.8%	74,928	20.7%
America	15,154	7.9%	20,342	6.8%	23,149	5.9%	23,635	9.5%	27,202	7.5%
Europe	10,417	5.4%	16,438	5.5%	22,475	5.7%	12,792	5.2%	18,117	5.0%
Asia	13,780	7.2%	22,080	7.4%	29,052	7.4%	22,290	9.0%	28,960	8.0%
Other regions	251	0.1%	409	0.1%	539	0.1%	314	0.1%	647	0.2%
Total Consolidated net sales	192,639	100.0%	297,681	100.0%	392,119	100.0%	247,769	100.0%	362,278	100.0%

3. Trends in other income

Millions of yen, rounded down

	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009	
	Interim results	Apr. - Dec. results	Full year results	Interim results	Apr. - Dec. results
Other income	2,521	3,510	4,863	3,093	3,736
Interest income	225	361	528	351	534
Dividend income	743	1,235	1,274	668	975
Foreign exchange gain	--	--	--	442	--
Income from equity method investments	502	754	1,125	694	995
Other	1,050	1,158	1,935	936	1,230
Other expenses	2,687	3,165	6,257	1,899	3,166
Interest expense	171	250	327	300	413
Foreign exchange loss	307	254	1,034	--	555
Loss from disposal of fixed assets	484	630	1,441	856	1,205
Other	1,724	2,029	3,453	742	991

4. Trends in extraordinary income / losses

Millions of yen, rounded down

	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009	
	Interim results	Apr. - Dec. results	Full year results	Interim results	Apr. - Dec. results
Extraordinary income	328	7,562	7,988	--	--
Gain on sale of fixed assets	328	7,562	7,471	--	--
Other	--	--	517	--	--
Extraordinary losses	406	808	7,169	4,769	13,981
Loss from revaluation of investment securities	--	--	--	180	5,266
Integration-related expenses	--	518	2,831	1,895	4,084
Compensation payments	--	--	--	--	1,937
Asset impairment losses	--	289	2,264	1,931	1,931
Extraordinary depreciation of fixed assets	--	--	--	762	762
Losses from revaluation of investments in affiliates	--	--	1,372	--	--
Provisions for loss on guarantees	--	--	700	--	--
Transfer to allowance for bad debt	406	--	--	--	--

5. Trends in R&D expenses

Billions of yen, rounded down

	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009		
	Interim results	Apr. - Dec. results	Full year results	Interim results	Apr. - Dec. results	Full year forecast
R&D (Consolidated)	18.8	26.0	34.1	25.9	36.9	51.7
R&D to Net sales ratio	9.8%	8.8%	8.7%	10.5%	10.2%	11.3%
Pharmaceuticals	15.8	21.5	28.1	23.0	32.5	45.1
R&D to Net sales ratio	23.0%	20.3%	20.4%	21.2%	20.2%	21.6%
Bio-Chemicals	1.9	2.9	3.9	1.8	2.7	4.2
Chemicals	0.5	0.7	1.0	0.5	0.8	1.3
Food	0.4	0.7	0.9	0.4	0.6	0.9
Other	0.0	0.0	0.0	0.0	0.0	0.0

6. Trends in capital expenditure

Billions of yen, rounded down

	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009		
	Interim results	Apr. - Dec. results	Full year results	Interim results	Apr. - Dec. results	Full year forecast
Capital expenditure (Consolidated)	7.7	11.1	14.7	8.5	12.9	23.5
Pharmaceuticals	1.4	2.8	4.2	3.6	5.5	12.4
Bio-Chemicals	2.0	3.1	4.1	2.0	3.8	5.7
Chemicals	2.5	3.2	4.3	2.4	2.9	4.7
Food	1.6	1.7	1.9	0.3	0.4	0.4
Other	0.0	0.0	0.0	0.0	0.0	0.0
Eliminations	--	--	--	(0.0)	(0.0)	(0.0)

7. Trends in depreciation expenses

Billions of yen, rounded down

	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009		
	Interim results	Apr. - Dec. results	Full year results	Interim results	Apr. - Dec. results	Full year forecast
Depreciation expenses (Consolidated)	6.7	10.4	14.3	9.6	14.3	20.0
Pharmaceuticals	1.8	2.8	3.9	4.6	6.6	9.2
Bio-Chemicals	2.6	4.0	5.5	2.4	3.7	5.3
Chemicals	1.7	2.7	3.7	2.0	3.0	4.3
Food	0.4	0.6	0.9	0.4	0.7	0.9
Other	0.0	0.0	0.1	0.0	0.0	0.1
Eliminations	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)

8. Trends in key indicators

(1) Exchange rate

	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009		
	Interim results	Apr. - Dec. results	Full year results	Interim results	Apr. - Dec. results	Full year forecast
US Dollar (yen/US\$)	119	117	114	106	103	100
Euro (yen/Euro)	162	163	162	163	151	143

(2) Operating indicators (Consolidated)

	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009	
	Interim results	Apr. - Dec. results	Full year results	Interim results	Apr. - Dec. results
Net income per share (yen) (Before goodwill amortization)	27.77	60.55	59.03	14.43 (22.79)	18.26 (30.80)
Operating income to sales ratio (%)	9.5	10.9	10.0	11.8	11.8
Total assets (million yen)	396,667	403,088	394,081	748,454	725,893
Net assets (million yen)	252,211	260,841	256,758	551,817	544,037
Equity ratio (%)	62.9	64.1	64.5	73.1	74.3
Net assets per share (yen)	627.70	649.69	639.69	952.77	939.72
ROIC (Return on invested capital)* (%)	6.3	11.0	13.8	8.2	12.1
No. of staff at end of term (consolidated)	6,111	--	6,073	7,868	7,856

$$* \text{ROIC} (\%) = \frac{\text{Operating income}}{(\text{Fixed assets} + \text{Working capital})} \times 100$$

Note: Calculations are based on operating income before amortization of goodwill and fixed assets not including goodwill.

IV. Subsidiaries and affiliates

(As of December 31, 2008)

Segment	Type	Company name	Percentage owned (direct and indirect)	Principal business
Pharmaceuticals	Consolidated subsidiary	Kyowa Medex Co., Ltd.	100.0%	Manufacture and sale of diagnostic reagents
		Kirin Kunpeng (China) Bio-Pharmaceutical Co., Ltd.	70.0%	Manufacture and sale and of pharmaceuticals (China)
		Kyowa Medical Promotion Co., Ltd.	100.0%	Sales promotion of pharmaceuticals
		Kyowa Hakko Kirin America, Inc.	100.0%	Holding company for administration and management of US subsidiaries (US)
		BioWa, Inc.	100.0%	Out-licensing and promotion of anti-body technology and development of therapeutic antibodies (US Company)
		Kirin Pharma USA, Inc.	100.0%	Generate new candidate substances and develop pharmaceuticals (US)
		Hematech, Inc.	100.0%	Technology research for manufacture of therapeutic antibody (US)
		Hematech-GAC Venture, LLC	51.0%	Technology research for manufacture of therapeutic antibody (US)
		Jeil-Kirin Pharmaceutical Inc.	90.0%	Sales of pharmaceuticals (Korea)
		Kirin Pharmaceuticals Co., Ltd.	100.0%	Sales of pharmaceuticals (Taiwan)
		Kirin Pharmaceuticals Co., Ltd.	100.0%	Sales of pharmaceuticals (Hong kong)
		Kyowa Hakko Kirin (Singapore) Pte. Ltd.	100.0%	Sales of pharmaceuticals (Singapore)
Kyowa Hakko Kirin (Thailand) Co., Ltd.	100.0%	Operations suspended June 30, 2008		
Bio-Chemicals	Consolidated subsidiary	Kyowa Hakko Bio Co., Ltd.	100.0%	Manufacture and sale of pharmaceutical and industrial raw materials, and health care products
		Daiichi Fine Chemical Co., Ltd.	100.0%	Manufacture and sale of active pharmaceutical ingredients and pharmaceutical intermediates
		Biokyowa Inc.	100.0%	Manufacture and sale of amino acids (US Company)
		Shanghai Kyowa Amino Acid Co., Ltd.	70.0%	Manufacture and sale of amino acids (China Company)
		Kyowa Hakko U.S.A., Inc.	100.0%	Sale and import/export of fine chemicals including amino acids (US Company)
		Kyowa Hakko Europe GMBH	100.0%	Sale and import/export of fine chemicals including amino acids (Germany Company)
		Kyowa Italiana Farmaceutici S.R.L.	100.0%	Sale and import/export of fine chemicals including amino acids (Italy Company)
		Kyowa Hakko (H.K.) Co., Ltd.	100.0%	Sale and import/export of fine chemicals including amino acids (Hong Kong Company)
		Kyowa Hakko Bio U.S. Holdings, Inc.	100.0%	Holding company for administration and management of US subsidiaries (US)
		Kyowa Wellness Co., Ltd.	100.0%	Sale of healthcare products
Shinwa Pharmaceutical Co., Ltd.	100.0%	Sale of herbal medicines and health foods		
		Kyowa Engineering Co., Ltd.	100.0%	Design and installation of plant facilities and equipment
Chemicals	Consolidated subsidiary	Kyowa Hakko Chemical Co., Ltd.	100.0%	Manufacture and sale of chemicals
	Affiliate accounted for by the equity method	J-PLUS Co., Ltd.	50.0%	Manufacture and sale of plasticizers
		Kurogane Kasei Co., Ltd.	40.0%	Manufacture and sale of plasticizers, fine chemicals, etc.
Food	Consolidated subsidiary	Kyowa Hakko Food Specialties Co., Ltd.	100.0%	Manufacture and sale of seasonings, bakery products and ingredients and other foods
		Kyowa F.D. Foods Co., Ltd.	100.0%	Manufacture and sale of freeze-dried foods
		Ohland Foods Co., Ltd.	100.0%	Manufacture and sale of bakery products, etc.
		Kyowa HiFoods Co. Ltd.	100.0%	Import and sale of foods, etc.
	Affiliate accounted for by the equity method	Aji-Nihon Co., Ltd.	46.3%	Manufacture and sale of foods and seasonings, etc.
		Zenmi Foods Inc.	50.0%	Manufacture and sale of seasonings
Other	Consolidated subsidiary	Miyako Kagaku Co., Ltd.	52.9%	Wholesale sales of pharmaceuticals, chemicals, foods, etc.
		Chiyoda Kaihatsu Co., Ltd.	100.0%	Transportation, insurance, sale of food, etc.
		Kashiwagi Corporation	56.0%	Wholesale sales of chemicals, pharmaceutical products, construction materials, etc.
	Affiliate accounted for by the equity method	Japan Synthetic Alcohol Co., Ltd.	33.3%	Manufacture and sale of industrial use alcohol

Changes to the scope of consolidation

Newly consolidated: Two companies: Kirin Pharma Company, Limited and Kyowa Hakko Bio Co., Ltd.

Eliminated: One company: Kirin Pharma Company, Limited

III. Net sales by division (Items and main products presented on a non-consolidated basis)

1. Kyowa Hakko Kirin Co., Ltd.

Billions of yen, rounded down

Pharmaceuticals division (Non-Consolidated)	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009				
	Interim results	Apr. - Dec. results (A)	Full year results	Interim results	Apr. - Dec. results (B)	Change (B-A)	Full year forecast (As of Oct. 31)	Full year forecast (Revised)
Pharmaceuticals division total	62.9	97.1	127.3	99.2	147.5	50.4	188.3	188.3
Central nervous system agents								
Depakene	5.2	8.3	10.5	5.3	8.3	0.0	10.7	10.7
Topina	--	--	0.1	0.3	0.6	0.6	1.0	1.0
Sensory organ agents								
Patanol	0.8	1.5	4.3	1.4	2.2	0.7	4.9	4.9
Circulatory organ agents								
Coniel	13.2	20.2	25.4	11.6	18.1	(2.1)	22.9	22.9
Inovan + Pre Dopa	2.0	3.2	4.1	1.8	2.9	(0.3)	3.7	3.7
Coversyl	--	--	--	2.6	4.0	4.0	5.0	5.0
Digestive organ agents								
Nauzelin	2.6	4.7	6.1	2.4	4.2	(0.5)	5.7	5.7
Other metabolic medicines								
NESP/ESPO	--	--	--	21.3	34.4	34.4	43.0	43.0
REGPARA	--	--	--	1.9	3.3	3.3	4.2	4.2
Blood and humoral applications								
Gran/Neu-up	2.3	3.6	4.4	9.1	14.3	10.7	18.3	18.3
Anticancer agents								
Farmorubicin + Adriacin	4.4	7.0	8.7	3.8	5.9	(1.1)	7.7	7.7
5-FU	1.7	2.7	3.4	1.8	2.8	0.1	3.6	3.6
Navelbine	1.6	2.5	3.1	1.5	2.4	(0.1)	3.1	3.1
Antiallergic agents								
Allelock	9.5	15.2	23.3	9.6	15.6	0.4	23.1	23.1
Celtect	2.0	3.1	4.1	1.7	2.6	(0.5)	3.6	3.6
Others								
Durotep	7.1	11.5	13.9	--	--	(11.5)	--	--
Exports and Technology Out-Licensing	10.3	13.0	16.3	22.8	26.3	13.3	29.7	29.7

Note 1: Figures for Fiscal year ended March 31, 2008 are Kyowa Hakko non-consolidated figures and do not include Kirin Pharma.

Figures for the interim period of fiscal year ended March 31, 2009 are the sum of Kyowa Hakko non-consolidated figures and Kirin Pharma non-consolidated figures.

Note 2: Results based on settlement price on a shipment basis. Forecasts are based on an actual consumption basis.

Note 3: Fiscal year ended March 31, 2008 figures for Gran and Neu-up do not include sales for Gran by Kirin Pharma

2. Kyowa Hakko Bio Co., Ltd. (Non-consolidated)

Billions of yen, rounded down

Bio-Chemicals division (Non-Consolidated)	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009				
	Interim results	Apr. - Dec. results (A)	Full year results	Interim results	Apr. - Dec. results (B)	Change (B-A)	Full year forecast (As of October 30)	Full year forecast (Revised)
Bio-Chemicals division total	26.7	40.4	55.1	28.4	42.1	1.7	57.4	55.3
Pharmaceutical and Industrial raw materials								
Amino acids	9.6	14.5	20.1	10.2	14.9	0.4	20.7	19.1
Nucleic acids and vitamins	2.7	3.6	5.1	2.9	4.0	0.4	5.3	5.1
Health care products	3.9	5.8	7.6	4.2	6.2	0.4	8.3	8.1
Agrochemicals, livestock and fisheries products	1.6	2.5	3.8	1.6	2.5	0.0	3.7	3.7
Alcohol	4.5	7.1	9.4	4.6	7.2	0.1	9.4	9.4

Note: Figures for the fiscal year ended March 31, 2008 and figures for the interim results of the fiscal year ending March 31, 2009 are figures for Kyowa Hakko Kogyo Co., Ltd. Bio-Chemical division.

3. Kyowa Hakko Chemical Co., Ltd. (Non-consolidated)

Billions of yen, rounded down

Chemicals division (Non-Consolidated)	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009				
	Interim results	Apr. - Dec. results (A)	Full year results	Interim results	Apr. - Dec. results (B)	Change (B-A)	Full year forecast (As of October 30)	Full year forecast (Revised)
Chemicals division total	51.0	80.0	107.9	57.1	77.3	(2.7)	120.0	90.0
Solvents	24.3	37.9	50.3	25.5	35.0	(2.9)	52.5	40.5
Raw materials for plasticizers	15.4	24.7	33.4	19.7	25.9	1.2	41.0	30.0
Specialty chemicals	8.7	13.6	19.3	9.7	13.2	(0.4)	21.7	16.3

4. Kyowa Hakko Food Specialties Co., Ltd. (Non-consolidated)

Billions of yen, rounded down

Food division (Non-Consolidated)	April 1, 2007 to March 31, 2008			April 1, 2008 to March 31, 2009				
	Interim results	Apr. - Dec. results (A)	Full year results	Interim results	Apr. - Dec. results (B)	Change (B-A)	Full year forecast (As of October 30)	Full year forecast (Revised)
Food division total	18.5	29.4	38.4	18.8	29.8	0.4	38.5	38.5
Natural seasonings	7.4	11.9	15.3	7.3	11.7	(0.2)	15.8	15.8
Umami seasonings	2.0	3.3	4.4	2.4	3.8	0.5	4.3	4.3
Bakery ingredients and products	4.6	6.7	8.8	4.2	6.5	(0.2)	8.7	8.7
Processed foods	3.1	5.3	7.0	3.1	5.0	(0.3)	6.7	6.7

R&D PIPELINE

Kyowa Hakko Kirin

Jan 30th 2009

Category	Code Name Product Name	Generic Name	Stage		Indication	Formulation	In-house OR Licensed	Remarks
			Japan	Other countries				
Cancer/Hematology	KRN321 NESP	Darbepoetin Alfa	Filed Nov/2008		☆ Anemia (After chemotherapy for cancer)	Injection	Kirin-Amgen	Long-acting erythropoiesis stimulating protein An approval has been given in Japan for anemia of CKD patients on dialysis. In development since July 2007.
	AMG531	Romiplostim	Phase III		Ideopathic thrombocytopenic purpura	Injection	Kirin-Amgen	Thrombopoiesis stimulating peptibody. (Contractual based development with Amgen Development Inc.)
	KW-2246	Fentanyl citrate	Phase III		Cancer pain	Sublingual tablet	Licensed from Orexo.	
	KRN125	Pegfilgrastim	Phase II		Neutropenia	Injection	Kirin-Amgen	Long-acting G-CSF
	AGS-003			Phase II in USA and Canada	Renal Cell Carcinoma	Injection	Developed with Argos.	Dendritic cell-based immunotherapeutics
	AGS-004			Phase II in Canada	HIV	Injection	Developed with Argos.	Dendritic cell-based immunotherapeutics
	KRN654	Hydrochloric acid agrylin	Phase I / II		Essential thrombocythemia	Oral	Licensed from Shire.	
	KW-0761		Phase I		Cancer (Hematologic tumor)	Injection	Developed In-house	Humanized monoclonal antibody
	KW-2449			Phase I in USA	Cancer	Oral	Developed In-house	
	KW-2478			Phase I in Europe	Cancer	Injection	Developed In-house	
	ARQ 197		Phase I		Cancer	Oral	Licensed from ArQule.	
	KRN 330			Phase I in USA	Cancer	Injection	Developed In-house	Fully human monoclonal antibody
Kidney	PB94 PHOSBLOCK (RENEGAL)	Sevelamer Hydrochloride		Filed in China Jun/2008	Hyperphosphatemia	Oral	Licensed from Chugai.	Launched in Japan
	KRN 321 NESP	Darbepoetin Alfa	Filed Dec/2008	Phase II in China	☆ Anemia	Injection	Kirin-Amgen	Long-acting erythropoiesis stimulating protein. Approval granted for anemia of CKD patients on dialysis in Japan. In development since July 2007.
Immunity/Allergy	KW-4679 ALLELOCK	Olopatadine Hydrochloride		Filed in China Jul/2008	Antiallergic	Oral	Developed In-house	Launched in Japan
	Z-206 ASACOL	Mesalazine	Phase III		Inflammatory bowel disease (Crohn's disease)	Oral (pH depend controlled-release formulation)	Licensed from Zeria Pharma.	Jointly developed with Zeria Pharma.
	NU206			Phase I in Australia	Inflammatory bowel disease	Injection	Developed with Nuvelo.	
	ASKP1240			Phase I in USA	Organ Transplant Rejection	Injection	Developed with Astellas.	Fully human monoclonal antibody
CNS	KW-6002	Istradefylline	Phase II b	Filed in USA Apr/2007	Parkinson's disease	Oral	Developed In-house	☆ Clinical trials for monotherapy: Phase II a, in Japan
	KW-6500	Apomorphine Hydrochloride	Phase II		Parkinson's disease	Injection	Licensed from Britannia Pharma.	
Cardiovascular	KW-3049 CONIEL	Benidipine Hydrochloride		Approved in China Sep/2008	☆ Angina	Oral	Developed In-house	☆ Launched for Hypertension in China in Dec 2004
Other	KW-7158		Phase II a		Bowel disease (Irritable bowel syndrome)	Oral	Developed In-house	Development program for KW-7158 (Phase II a clinical trials) Overactive bladder/Urinary incontinence was discontinued in Sep 2006.
	KW-3357	Antithrombin	Phase I		Blood coagulation factor inhibitor (Disseminated intravascular coagulation)	Injection	Developed In-house	Recombinant antithrombin product
	KRN23			Phase I in USA	Hypophosphatemic disease such as X-linked Hypophosphatemia (XLH)	Injection	Developed In-house	Fully human monoclonal antibody

Note: In Japan, application for approval of renal anemia (pre-dialysis treatment) for KRN321NESP (renal area) has been filed. (In China, development on anemia during dialysis is in progress)

Additional pipeline products:

In the Philippines, approval for Filgrastim(G-CSF) has been filed

In Korea, Taiwan and Thailand, approval for NESP(long-acting erythropoiesis stimulating protein) has been filed

In Hong Kong and Taiwan, REGPARA (a treatment for secondary hyperthyroidism during dialysis therapy) has been filed

In Korea, REGPAPA clinical pharmacological tests are underway

Updated since October 30th, 2008 (Area, Stage, Filed, Approved, Launched etc.)

☆ New indication